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Chapter 7
Summary and General Discussion
Summary
The studies described in this thesis focus on the problem of renal chronic function loss
following solid organ transplantation from a nephrologist point of view. Nephrologists have
been and are still confronted with renal function loss in native kidney diseases. The last 3
decades chronic renal function loss has become an important item after renal transplantation.
In renal transplantation, due to the greatly improved short-term results, a clear shift in
attention and research from the peri- and early post-transplantation phase to the long-term
follow up is made.  However, intriguingly one does not only observe chronic renal function
loss after renal transplantation. Renal function also deteriorates shortly after transplantation
of other organs such as lung, liver and heart. In non-renal solid organ transplantation, with
it’s generally shorter history, progressive renal function loss poses an important and
clinically relevant problem as well, but has so far not been extensively studied. Given the
experience obtained in renal transplant recipients nephrologists, as described in chapter 1,
may have an important role in the necessary efforts to identify patients at risk and develop
renoprotective strategies in the non-renal solid organ transplant recipients.
Monitoring of renal function is a prerequisite to study renal function loss or to evaluate the
impact of intervention on renal function. Serum creatinine is commonly used as a measure
of renal function. However, after solid organ transplantation great changes in creatinine
generation and excretion may occur, which may compromise the accuracy of 
creatinine-based renal function assessment. In order to assess the reliability of the
creatinine-based methods to detect renal function loss in this population in chapter 2 we
compared these methods with the golden standard of measurement of glomerular filtration
rate every 6 months after transplantation in a cohort of 40 lung transplant recipients followed
for at least 24 months. The rate of renal function loss calculated from the slope of measured
glomerular filtration rate and the commonly used creatinine-based indices 1/SCreatinine,
Cockcroft clearance, and the Levey formula correlated significantly. However, all
creatinine-based slopes underestimated the rate of renal function loss by 20 to 30% and are
less accurate to detect small losses in glomerular filtration rate. The discrepancy between
measured glomerular filtration rate and creatinine-based measures of renal function proved
to be dependent on the time of follow up since transplantation. This may explain the
consequent underestimation and proves that creatinine generation and excretion is not stable
following lung transplantation. Therefore, these methods are not well suited to study renal
function loss in this population. 
The next studies describe serial measurements of glomerular filtration rate following lung
transplantation. These studies were performed to elucidate the course of renal function loss
after lung transplantation and to determine possible predictors of this renal function loss. In
chapter 3 we report renal haemodynamics in 44 patients before and at several points after
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lung transplantation. A substantial decline in renal function occurred, with a progressive fall
in GFR of 33% at 12 months and 42% at 30 months after transplantation. Effective renal
plasma flow fell by 22% at 12 months and remained stable thereafter. After transplantation
blood pressure and renal vascular resistance increased significantly, consistent with the
effect of cyclosporin A. Prior to transplantation, renal function impairment with signs of
intense renal vasoconstriction was found in a subset of the patients. As especially lung
transplant recipients with pulmonary hypertension showed this pre-transplant renal
haemodynamic profile, the suggestion is that this profile may be secondary to right sided
cardiac failure. Remarkably, the decrease in renal function after transplantation was less
pronounced in patients with renal function impairment prior to transplantation: a significant
negative correlation between pre-transplantation GFR and ERPF and the percentage change
in GFR and ERPF  after transplantation was found. These findings suggest that renal
function impairment in combination with intense renal vasoconstriction prior to lung
transplantation may be functionally and not structurally, and that the net course of renal
function impairment after lung transplantation is the result of the opposed effects of
cyclosporin nephrotoxicity on the one hand and the favorable effects of the normalization of
respiratory or cardiopulmonary status on renal perfusion on the other hand. 
In chapter 4 we extended the data on renal function before, at 1 month, and every 6 months
following transplantation in 57 lung transplant recipients with at least 24 months of follow
up. A clear biphasic pattern of renal function loss was found. The glomerular filtration rate
decreased profoundly from 100 ml/min before transplantation to 67 ml/min at six months
after transplantation with most of the loss already present at 1 month. From 6 months after
transplantation onwards it was followed by a more gradual decline with a GFR of 53 ml/min
at 24 months and 51 ml/min at 36 months after transplantation. The magnitude of the loss of
GFR at 1 month after transplantation was the only factor significantly correlated with
absolute GFR at 24 months after transplantation, which was one of the endpoints of the
study. Another marker of renal progression, the slope of GFR as of 6 months after
transplantation, was found to be significantly associated with pulmonary diagnosis. Median
loss was greatest in patients with cystic fibrosis (-10 ml/min/yr), preserved in pulmonary
hypertension (-1 ml/min/yr) and in-between in patients with emphysema (-6 ml/min/yr). No
other factors could be identified. Given the large and lasting negative impact of early renal
function loss on renal prognosis, the obvious next step was to analyze determinants for renal
function loss at 1 month after transplantation. To this purpose we analysed in chapter 5 a
cohort of 83 recipients after lung transplantation. Pre-transplant characteristics,
haemodynamical peri-operative parameters, complications, and treatment modalities
occurring during the first month were correlated to the change in GFR between pre- and 1
month post-transplantation. The mean decline in GFR in the first month was –23 ml/min.
Multivariate regression analysis identified a higher pre-transplant GFR, a bilateral
98
SUMMARY AND GENERAL DISCUSSION
transplant, post-operative surgical revision for bleeding and a diminished diuresis and a
prolonged period of mean arterial pressure < 70 mmHg in the first 24 hours after
transplantation as factors independently associated with a greater decline in GFR at 1
month post-transplantation. Four of these five factors are indicative for peri-operative
haemodynamic instability and these risk factors appear to be highly comparable with other
populations in the peri-operative phase. On the other hand, a higher pre-transplant GFR as
a risk factor for early renal function loss and the fact that renal function loss is irreversible
are remarkable findings that appear to be specific for this population. As a rule renal
function impairment is reported to be a risk factor for post-operative renal failure. The
explanation of this discrepancy may be the diversity in course of renal function for patients
with different pulmonary diagnosis. A significant difference was apparent between
diagnosis groups in both pre-transplant as well as post-operative renal function loss. In this
population a compromised renal function may be due to intense renal vasoconstriction, as
in patients with pulmonary hypertension, and improvement of cardiopulmonary status may
restore renal perfusion. A higher GFR, as in cystic fibrosis, may reflect glomerular
hyperfiltration making them especially vulnerable for nephrotoxic insults. The impact of
diagnosis is clearly of clinical relevance but it raises the question whether pulmonary
diagnosis is a risk factor or merely a marker for a favourable or poor risk factor profile. Our
results show that the risk factors associated with early renal function loss are not evenly
distributed over the diagnosis groups supporting the assumption that pulmonary diagnosis
is associated with clustering of renal risk factors. 
An important result from this analysis is that patients at risk for renal function loss after
lung transplantation can be identified as early as one month after or even prior to
transplantation. Attention can and should, therefore, be focussed on renoprotective
measures in high risk patients. Whether it will be possible to improve short and long-term
renal prognosis in this particular population by additional renoprotective interventions
remains to be investigated. Chronic renal function loss occurs in a substantial proportion of
patients with an initially successful renal transplantation as well. Until now multiple risk
factors, immunological and non-immunological, have been identified, suggesting that its
pathogenesis is multifactorial. Some of these factors, such as HLA-mismatching and
previous rejection episodes are specific for renal transplants, whereas others, such as high
blood pressure, a compromised renal function and proteinuria are risk factors common to
both native and transplanted kidneys. Genetic factors may also play a role in long-term
renal prognosis after renal transplantation. The renin-angiotensin-aldosterone system is, as
proven in many experimental and human studies, involved in progression of renal disease.
The angiotensin-converting enzyme (ACE) gene may influence this system and has been




Whether this ACE (I/D) gene and therefore the RAAS-system plays a role in graft survival
after renal transplantation justifies further research in this population. In contrast with the
group of recipients after lung transplantation the group of patients after renal
transplantation is large enough to analyze the influence of ACE genotype on renal survival.
To this purpose we studied in chapter 6 a group of 435 patients who received a cadaveric
renal transplant. We conducted our analysis in 367 patients with a functioning graft at 12
months after transplantation to avoid bias by acute pathology, such as technical failure and
therapy resistant episodes of acute rejection. Patients dying with a functioning graft were
censored and donor and recipient ACE (I/D) genotype had to be available. The latter might
allow to distinguish between the influence of tissue and systemic ACE genotype and thus
could provide a clue to the mechanism of action of the impact of ACE-genotype in renal
disease. We found that in the group as a whole graft loss in DD genotype was worse,
however, no statistical significance could be found. In patients with a high risk for graft loss
we found an association between recipient, but not donor, ACE gene D-allele and time to
graft loss. This relation could only be demonstrated after controlling for other risk factors
for graft loss by multivariate analysis. This suggests that an adverse effect of the D-allele on
renal prognosis is present but only becomes manifest when other risk factors for graft loss
are simultaneously present. Recipient ACE gene D-allele plays an independent role in long-
term graft survival after renal transplantation. This D allele is reported to be associated with
higher systemic ACE levels and may therefore modify the renin-angiotensin-aldosterone-
system. Whether genetic factors such as the ACE (I/D) genotype also influence renal
survival in lung transplant recipients has still to be investigated. In our series, the group of
recipients after lung transplantation is still too small. However, the number of patients
living long enough after lung transplantation is increasing.
General discussion
Almost a decade ago, the lung transplantation program started in our center. At the time,
renal transplantation already had a history of more than 25 years. From the 10-year
experience with the use of cyclosporin A in this renal population, the awareness of its
nephrotoxicity was well-established. However, the relative contribution of cyclosporin
nephrotoxicity in chronic long-term function loss in renal allografts had – and still has – not
been delineated. Not only in renal allografts1 but also in subjects with non-renal disorders2,3
treatment with cyclosporin A had been shown to exert nephrotoxic effects.
The experience with solid organ transplantation other than the kidney – although in smaller
populations and with shorter duration of follow up – had already pointed towards obvious
renal function loss after transplantation. However, it was also clear that the severity of renal
function loss in native kidneys was very different for different transplant populations. It
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was relatively mild – and hardly leading to clinical symptoms – in liver transplant
recipients4, but in heart- and lung-transplant recipients renal function loss had been
observed with progression towards end-stage renal failure in approximately 10 percent of
the patients five year after transplantation5.
From this state of knowledge, at the start of the lung transplantation program it could be
anticipated that renal function loss would occur in this particular population. As to its
severity and clinical impact however, no valid prediction could be made. Triggered by the
renal abnormalities in the first patients screened for transplantation – all with pulmonary
hypertension – and faced with the prospect of a population at a certain, but undefined, renal
risk, it was decided to include renal monitoring in the work up and follow up of this
particular population6. The purpose of this renal program was to identify, within the shortest
possible time-frame, the nature and magnitude of short- and long-term renal function loss in
this particular population in order to be able to develop renoprotective strategies if needed.
To this purpose, a close renal monitoring strategy was followed, based on serial renal
haemodynamic measurements. Renal haemodynamics were measured during the work up
for transplantation and at one month after transplantation – i.e. the patients being free from
post-operative instability and complications – and subsequently at six-month intervals. This
particular monitoring schedule – renal haemodynamics at six month intervals – was
adopted because prior studies by Apperloo et al. on long-term renal function loss in chronic
renal patients had shown that his approach allows to define the rate of renal function loss
with great accuracy, within a relatively short time-frame7. Moreover, the unreliability of
creatinine measurements during cyclosporin treatment, as well as the anticipated specific
renal haemodynamic effects of cyclosporin were reasons not to rely on creatinine-based
renal function parameters in the renal monitoring of this population, but to use iothalamate
clearances. The renal monitoring schedule was implemented immediately after the start of
the first lung transplantations in our center. Consequently, we now avail of a unique series
of observations, including pre-transplant renal haemodynamics, in virtually all transplanted
patients.
The purposes of the renal monitoring program in the lung transplant population can be
summarized as follows. First, we pursued the descriptive characterization of renal function
loss in lung transplant recipients to define the severity of renal risk in this specific
population. The next purpose, once it had become apparent that renal morbidity was
considerable, was to attempt to identify the risk factors for renal function loss in this
population, in order to enable to design preventive strategies. In this respect we sought for
patient-related risk factors – i.e. factors that can be identified already before transplantation,
thus allowing pre-operative risk assessment – and treatment-related risk factors, that can
potentially be modified by adapting treatment protocols. In addition, we evaluated the
monitoring strategy itself, in order to develop a future monitoring strategy that is both
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simple and effective, i.e. validated for correct identification of renal function loss, and
suitable to identify high risk patients at an early stage.
Descriptive characterization
Renal function loss after lung transplantation is considerable and a clinically relevant
problem and the course of renal function loss in recipients after lung transplantation shows a
biphasic pattern8,9. The greatest amount of renal function is lost in the first 6 months and
thereafter it is stabilizing in a subset of patients but in the majority of the patients renal
function is declining with a great between-patient variability. The rate of renal function loss
as of 6 months after transplantation was analysed by linear regression9. Whether the decline
of renal function in this specific population on long-term remains a linear process is
uncertain. Indeed, until now our long-term observation suggests a tri-phasic pattern with
stabilization of renal function after initial loss of renal function. This observation has clearly
impact on clinical as well as analytical evaluation of this population. Further follow up and
separate long-term analyses may have to be performed to answer specific questions. 
Within the group of lung transplant recipients as a whole a heterogeneity in renal function
characteristics is present and differences in pre-transplant GFR may not merely reflect
quantitative differences in prior renal damage. Recipients with a compromised renal
function pre-transplantation characterized by intense renal vasoconstriction, as in patients
with pulmonary hypertension, appeared to be protected against severe renal function loss
after transplantation whereas a higher pre-transplant GFR, as in cystic fibrosis, appeared to
be a risk factor for a worse long- and short-term renal prognosis8,9.
Identification of risk factors
Cyclosporin A plays without any doubt an important role in the process of renal function
loss after solid organ transplantation, but the diversity in the course of renal function in the
population after renal and lung transplantation makes clear that cyclosporin is not the only
factor responsible for this loss, unless cyclosporin toxicity varies widely between different
individuals. In renal transplant recipients the course of graft survival is diverse as well. As in
other renal populations10 the ACE (I/D) genotype also affected renal survival in renal
transplant recipients. Those recipients with the DD genotype and a worse renal function
and/or proteinuria at 1 year after transplantation are at risk for early graft loss11. 
Our analysis in lung transplant recipients until now has shown that the first blow seems to be
half the battle. This means that the amount of early renal function loss has major impact on
long-term renal prognosis. Pulmonary diagnosis appeared to be a relevant factor as well9.
Risk factors for early renal function loss tend to cluster with pulmonary diagnosis: 
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peri-operative haemodynamic compromise affecting renal perfusion and pre-transplant GFR
play an important role in short-term renal function loss and therefore on long-term renal
prognosis12. Further and longer follow up in a greater number of patients will be needed to
answer questions about other risk factors for renal function loss in this specific population.
Preventive strategies
Identifying patients at risk for renal function loss in the population of recipients after solid
organ transplantation gives us the opportunity to start preventive strategies in recipients at
risk. In native kidneys the renin-angiotensin-aldosterone system plays an important role in
progression of renal disease13 and the use of ACE-inhibitors is a current intervention to
preserve renal function14. We found that the DD-genotype of this system, associated with
higher ACE-levels, is a risk factor for graft loss after renal transplantation in high risk
groups11. Early introduction of an ACE-inhibitor could therefore be a possible intervention to
preserve graft function in high risk groups with a compromised renal function and/or
proteinuria at 1 year after transplantation. Starting-point could also be to strive for an
optimal renal function at 1 year without proteinuria. Better donor selection, living donor
transplantation or reducing the number of episodes with rejection by further improvement of
immunosuppressive medication could also be tools to improve long-term graft survival.
Identification of lung transplant recipients at risk for renal function loss seems possible as
well. Renal perfusion plays, as we have found12, a crucial role in the first month after
transplantation. Therefore, trying to achieve an optimal volume status in the peri-operative
phase could be a target for future research. However, the perceived risk of pulmonary edema
or respiratory distress syndrome often precludes liberal fluid resuscitation in this population.
The use of cyclosporin, undermining renal perfusion, is still inevitable. Tapering cyclosporin
levels, preventing cyclosporin toxicity or postponing the introduction of cyclosporin until
recovery of renal perfusion could be tools to prevent further compromise of renal perfusion.
The development of less nephrotoxic but also strong immunosuppressive drugs should be
looked for. Whether, as in native kidneys15,16, good blood pressure control will positively
affect long-term renal prognosis in this population has still to be investigated. The choice of
drug, calcium-antagonists or ACE-inhibitors, is also a question that still has to be answered.
Monitoring renal function
In transplant recipients great changes in creatinine generation and excretion may occur
during follow up and therefore the reliability of the creatinine-based methods of renal
function assessment was questioned. Underestimation of the rate of renal function loss and
the inability to detect small GFR losses17 made clear that in specific clinical situations and in
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research programs these methods are not the proper tools to measure renal function.
However, the Levey method had the lowest treshold and the time dependent discrepancy
between this method and GFR is diminishing over time and we do not know whether it has
already levelled off. Longer follow up will learn us more about the accuracy of this method
in measuring renal function and if it can replace iothalamate clearances.
In the population after renal transplantation graft loss is used as a well known end-point in
most of the studies in this field. For preventive strategies in patients at risk for graft loss the
rate of renal function loss will probably give us more information about the effect of the
measures taken and strategies can be changed if the desired effect will not be reached. In the
population after renal transplantation changes in creatinine generation and excretion may, as
in lung transplant recipients, occur as well. Testing the reliability of the creatinine-based
methods to measure renal function in this population has to be performed if we want to use
the rate of renal function loss along with graft loss.
Graft survival or the rate of renal function loss, with the pitfalls mentioned earlier,  are not
the only or  proper ways to reflect changes in the kidney and other tools may be used to
identify patients at risk for renal function loss early after transplantation. Assessment of
renal damage by performing renal biopsy or measuring renal reserve capacity can learn us
more about the seriousness of the renal damage at a certain point and may be important
prognostic signs to identify patients at risk for end-stage renal disease. 
Conclusion
Renal function loss after solid organ transplantation is a clinically relevant problem and as
we have shown a multifactorial process. Pre-transplantation-, peri-operative- and patient
characteristics play a role and a multidisciplinary approach seems necessary. The Groningen
Lung Transplantation program proves that along with the surgeon, anaesthesist and intensive
care doctor the nephrologist plays an important role in attending recipients after solid organ
transplantation.
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